Harbin Shiheng Bioengineering Pharmaceutical

Harbin Shiheng Bioengineering Pharmaceutical is a Chinese biopharmaceutical company specializing in the development and large-scale production of recombinant protein therapeutics. Founded in 1994 and headquartered in Harbin, the company has established itself as a key player in the domestic market for cytokines and hematology-related biologics. Its core product portfolio includes recombinant human interferon alpha-2b, erythropoietin (EPO), and granulocyte colony-stimulating factor (G-CSF), which are used to treat viral infections, anemia, and chemotherapy-induced side effects. The company operates advanced GMP-certified manufacturing facilities and has historically been listed on China's National Equities Exchange and Quotations (NEEQ). Harbin Shiheng continues to focus on expanding its biological drug pipeline to address unmet needs in oncology and infectious diseases.